CDSCO Drops the Separate Export NOC for Approved r-DNA Drugs Exported Under New Brand Names

India's drug regulator has removed a paperwork hurdle for one of the country's most valuable export sectors — biologics. The Central Drugs Standard Control Organisation (CDSCO) has clarified that exporters of approved recombinant-DNA (r-DNA) drugs do not need a separate export No Objection Certificate (NOC) when the product is exported under a different brand name, provided the approved composition, specifications and strength remain unchanged. Eligible manufacturers can instead proceed through the State Licensing Authority (SLA) using the online licensing system. For India's biopharma exporters, this trims a recurring delay from the export workflow.

What Happened

Responding to repeated queries from manufacturers, CDSCO issued a clarification (circulated to state drug controllers around mid-October 2026) on whether a fresh export NOC is needed when an already-approved r-DNA product is shipped abroad under a new brand or trade name. The position, as reported:

• A separate export NOC may not be required where there is no change in the approved composition, specifications and strength of the product.
• The relaxation applies to products that already hold valid marketing authorisation in India and whose approved characteristics are unchanged — only the brand/trade name used for export differs.
• Eligible manufacturers can apply directly to the concerned State Licensing Authority (SLA) through the online licensing system, without first obtaining a separate CDSCO export NOC for the brand-name change.

The clarification specifically concerns recombinant biologics — the class that includes monoclonal antibodies, insulin analogues, recombinant hormones and growth factors.

As reported, the measure is a clarificatory notice rather than a numbered rule amendment; exporters should confirm the exact wording and any reference against CDSCO's own communication before relying on it.

Why / Background

Exporters frequently sell the same approved drug under different brand names in different markets, to match local marketing, partner or tender requirements. Until now, a brand-name variation could trigger a demand for a separate export NOC even though the underlying product — its composition, strength and specifications — was identical to the version already approved in India. That created avoidable back-and-forth with the regulator and slowed shipments, particularly for time-sensitive biologics orders.

By confirming that an unchanged product does not need a fresh NOC simply because the export carton carries a different name, CDSCO removes a duplicative step. It also fits a broader direction of travel in Indian drug regulation toward online, process-light facilitation — including the earlier move to route r-DNA manufacturing-licence applications through the Online National Drugs Licensing System (ONDLS) rather than on paper.

Who's Affected / Who Benefits

• Indian biopharma and biologics exporters shipping approved r-DNA products abroad under market-specific brand names.
• Manufacturers of monoclonal antibodies, insulin and insulin analogues, recombinant hormones and growth factors.
• Regulatory-affairs teams and consultants managing export documentation and SLA filings.
• Overseas buyers and partners that require local branding, who should see faster turnaround on Indian supply.

The benefit is concentrated among exporters whose only change is the brand name; where composition, specification or strength differs, the usual approvals continue to apply.

Operational Detail

• The relaxation is tied strictly to no change in approved composition, specifications and strength. Any substantive change takes the product outside this facilitation.
• Eligible exporters route their application through the State Licensing Authority via the online system, consistent with CDSCO's digital-first approach.
• Exporters should retain clear evidence linking the exported, differently-branded product to the existing Indian marketing authorisation, in case destination regulators or customs seek confirmation.

What Pharma Exporters Should Do Now

• Identify eligible SKUs. List the approved r-DNA products you export under alternate brand names with unchanged composition, specification and strength.
• Confirm the exact CDSCO wording. Obtain the clarificatory communication from CDSCO/your state drug controller and read the precise conditions before dropping the NOC step.
• Keep an authorisation trail. Maintain documentation mapping each export brand name to the underlying Indian marketing authorisation.
• Update SOPs. Revise your export regulatory SOPs and brief regulatory-affairs and logistics teams so they do not request a now-unneeded NOC.
• Flag any product changes. Where strength, specification or composition differs from the approved product, continue with the full approval route — the relaxation does not apply.
• Check destination requirements. Ensure the importing country's regulator accepts the branding and documentation you plan to use.

The Bigger Picture

Biologics and r-DNA therapeutics are a high-value, fast-growing slice of India's pharmaceutical exports, and competitiveness increasingly turns on speed and predictability of regulatory clearance as much as on manufacturing cost. By cutting a duplicative NOC for cosmetic brand-name changes, CDSCO lowers friction for exporters without diluting safety oversight — the substantive approval of the product itself is untouched. It is a small, practical facilitation that, multiplied across many shipments and markets, can meaningfully shorten export lead times.

Frequently Asked Questions

Does this remove all export NOCs for r-DNA drugs? No. It addresses the specific case of exporting an already-approved r-DNA product under a different brand name with no change in composition, specifications or strength. Other approvals continue to apply where relevant.

What if the strength or formulation differs from the Indian-approved product? Then the relaxation does not apply, and the usual approval route should be followed.

Where do I apply now? Eligible manufacturers can apply to the concerned State Licensing Authority through the online licensing system, without first seeking a separate CDSCO export NOC for the brand-name change.

Is there a notification number for this? As reported, it is a CDSCO clarificatory communication to state drug controllers rather than a numbered rule amendment. Confirm the exact reference with CDSCO.

Which products are covered? Approved recombinant-DNA biologics — such as monoclonal antibodies, insulin analogues, recombinant hormones and growth factors — that already hold valid Indian marketing authorisation.

Conclusion

CDSCO's clarification removes a needless step for biologics exporters: an approved r-DNA drug shipped under a new brand name, with its approved composition, specifications and strength intact, should no longer require a separate export NOC. Exporters should confirm the exact conditions, map their eligible products, and update their documentation workflow to capture the time saving — while keeping the full approval route for any product that genuinely changes.

This is a news summary based on reporting of a CDSCO clarification. Confirm the precise scope, conditions and any reference directly with CDSCO and your State Licensing Authority before changing your export documentation practice.